Metrics to compare | STTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTTKPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.6x | −2.8x | −0.3x | |
PEG Ratio | −0.25 | −0.29 | 0.00 | |
Price/Book | 3.6x | 3.5x | 2.6x | |
Price / LTM Sales | 768.8x | 14.6x | 3.1x | |
Upside (Analyst Target) | 89.3% | 114.3% | 48.5% | |
Fair Value Upside | Unlock | −11.3% | 6.3% | Unlock |
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.